Moleculin Biotech Inc (MBRX): $mbrx..$1.09...massive bid support on th...

S&P 500

US TECH 100

Dow Jones

Brent Oil

Bitcoin

News Focus

News Focus

Moleculin Biotech Inc (MBRX)

Keep Last Read

Next 10 Prev Next

TommyBoyTrader9460

Send PM Follow Ignore

Followers	0
Posts	63269
Boards Moderated	4
Alias Born	06/06/2012

TommyBoyTrader9460

Re: whytestocks post# 1095

Thursday, 04/18/2019 2:20:56 PM

Thursday, April 18, 2019 2:20:56 PM

$mbrx..$1.09...massive bid support on the l2!...should move up quickly here...

Keep Last Read

Next 10 Prev Next

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:

1D
1M
3M
6M
1Y
5Y

Detailed Quote

Recent MBRX News

Form 8-K - Current report • Edgar (US Regulatory) • 04/23/2026 12:25:26 PM
Moleculin’s Annamycin Extends Survival by More Than 60% in Metastatic Pancreatic Cancer Preclinical Models - Data Presented at AACR 2026 • GlobeNewswire Inc. • 04/23/2026 12:25:00 PM
Moleculin Announces Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting • GlobeNewswire Inc. • 04/21/2026 12:36:00 PM
Form 8-K - Current report • Edgar (US Regulatory) • 04/15/2026 03:40:38 PM
Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/15/2026 04:15:07 AM
Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 04/14/2026 09:26:57 PM
Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/14/2026 08:56:35 PM
Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 03/27/2026 08:01:09 PM
Moleculin Hits 45 Subject Enrollment Milestone, Triggering Final Countdown to Mid-2026 MIRACLE Trial Data Readout • GlobeNewswire Inc. • 03/23/2026 12:31:00 PM
Form 8-K - Current report • Edgar (US Regulatory) • 03/23/2026 12:30:09 PM
Form 8-K - Current report • Edgar (US Regulatory) • 03/19/2026 12:45:15 PM
Form 8-K - Current report • Edgar (US Regulatory) • 03/19/2026 12:35:12 PM
Moleculin to Present at 38th Annual ROTH Conference • GlobeNewswire Inc. • 03/17/2026 01:05:00 PM
Moleculin Releases Next CEO Corner Segment Highlighting MIRACLE Study • GlobeNewswire Inc. • 03/11/2026 01:00:00 PM
Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/09/2026 07:58:05 PM
Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 02/27/2026 07:09:49 PM
Form 8-K - Current report • Edgar (US Regulatory) • 02/20/2026 01:50:23 PM
Moleculin shares slide sharply after warrant exercise deal • IH Market News • 02/19/2026 03:46:31 PM
Moleculin Announces Exercise of Warrants for $8.3 Million Gross Proceeds • GlobeNewswire Inc. • 02/19/2026 01:39:00 PM
Form 8-K - Current report • Edgar (US Regulatory) • 02/18/2026 09:31:16 PM
Form 8-K - Current report • Edgar (US Regulatory) • 02/18/2026 01:20:16 PM
Moleculin MIRACLE Trial Delivers 40% Preliminary Blinded CRc Rate (n=30) • GlobeNewswire Inc. • 02/18/2026 01:20:00 PM
Form 8-K - Current report • Edgar (US Regulatory) • 02/17/2026 01:35:16 PM
Moleculin Announces Notice of Allowance for Japanese Patent Covering Annamycin • GlobeNewswire Inc. • 02/17/2026 01:35:00 PM
Moleculin Launches CEO Corner Platform to Share Strategic Insights • GlobeNewswire Inc. • 02/13/2026 01:32:00 PM

More MBRX News

InvestorsHub community

Register for free to join our community of investors and share your ideas

You'll also get access to streaming quotes, interactive charts, trades, portfolio, live options flow